EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Antimicrobial‐resistant Helicobacter pylori in Japan: Report of nationwide surveillance for 2018–2020

Tadayoshi Okimoto iD, Takashi Ando, Makoto Sasaki, Shoko Ono iD, Intetsu Kobayashi, Keigo Shibayama, Daisuke Chinda, Kengo Tokunaga, Shigemi Nakajima iD, Takako Osaki iD, Toshiro Sugiyama, Mototsugu Kato und 1 weitere

Helicobacter · 2024

DOI: 10.1111/hel.13028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Helicobacter, 2024. Verfasst von Tadayoshi Okimoto und 12 weiteren Autor:innen. Beteiligte Einrichtung: Committee on Surveillance of Antimicrobial-resistant Helicobacter pylori Strains, The Japanese Society for Helicobacter Research, Tokyo, Japan. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori, Anti-Infective Agents. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japanese Society for Helicobacter Research, Health Labour Sciences Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Antimicrobial therapy is necessary to eradicate Helicobacter pylori infection. The emergence of antimicrobial‐resistant bacteria poses a threat to continued treatment with antimicrobial agents. For those who prescribe antimicrobial therapy, it is necessary to constantly monitor the emergence of antimicrobial‐resistant bacteria.

Method

H. pylori clinical isolates were collected in Japan from August 2018 to December 2020 for antimicrobial susceptibility testing. The agar dilution method was used for the determination of the minimum inhibitory concentration (MIC) of clarithromycin (CLR), amoxicillin (AMX), metronidazole (MNZ), and sitafloxacin (STX).

Results

MICs for 938 H. pylori isolates were examined. The primary resistance rates of H. pylori clinical isolates for CLR, AMX, MNZ, and STX in Japan were 35.5%, 2.7%, 4.2%, and 27.6%, respectively. The primary resistance rates for CLR, AMX, and MNZ were significantly higher than those of the 2002–2005 isolates. The resistance rate for CLR was significantly higher in females (males: 30.7%, females: 41.5%, p < 0.001) and higher in the ≤29 years age group (54.8%) than in the other age groups, although there were no significant differences ( p = 0.104). The MNZ resistance rate was significantly higher in the ≤29 years age group than in the other age groups ( p = 0.004). The resistance rate for STX increased with age, but a significant difference was only seen between the 30–49 years age group and the ≥70 years age group ( p < 0.001), and the resistance rate was significantly higher in strains isolated in the Kyushu region than in the other regions ( p < 0.001).

Conclusions

The primary resistance rates for CLR, AMX, and MNZ of H. pylori clinical isolates in Japan were higher than those of the 2002–2005 isolates. Continuous surveillance is needed to monitor the trends in antimicrobial‐resistant H. pylori .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsHelicobacter pyloriAnti-Infective AgentsMaleFemaleHumansAdultMiddle AgedJapanDrug Resistance, BacterialAmoxicillinClarithromycinMetronidazoleMicrobial Sensitivity TestsAnti-Bacterial Agents

Stichwörter der Autor:innen

Helicobacter pyloriJapanantimicrobial resistancesurveillance

Substanzen

AmoxicillinAnti-Infective AgentsClarithromycinMetronidazoleAnti-Bacterial Agents

Autor:innen und Institutionen

  • Committee on Surveillance of Antimicrobial-resistant Helicobacter pylori Strains, The Japanese Society for Helicobacter Research, Tokyo, Japan.
  • Department of Gastroenterology, Oita Prefectural Hospital, Oita, Japan.
  • Department of Gastroenterology, Faculty of Medicine, Oita University, Oita, Japan.
  • Ando Clinic, Kyoto, Japan.
  • Department of Internal Medicine, Division of Gastroenterology, Aichi Medical University School of Medicine, Nagakute, Japan.
  • Division of Endoscopy, Hokkaido University Hospital, Sapporo, Japan.

ORCID-Profile: Tadayoshi Okimoto, Shoko Ono, Shigemi Nakajima, Takako Osaki, Kazunari Murakami

Förderung

  • Japanese Society for Helicobacter Research
  • Health Labour Sciences Research

Zitieren

APA

Okimoto, T., Ando, T., Sasaki, M., Ono, S., Kobayashi, I., Shibayama, K., Chinda, D., Tokunaga, K., Nakajima, S., Osaki, T., Sugiyama, T., Kato, M., & Murakami, K. (2024). Antimicrobial‐resistant Helicobacter pylori in Japan: Report of nationwide surveillance for 2018–2020. Helicobacter. https://doi.org/10.1111/hel.13028

Vancouver

Okimoto T, Ando T, Sasaki M, Ono S, Kobayashi I, Shibayama K, et al. Antimicrobial‐resistant Helicobacter pylori in Japan: Report of nationwide surveillance for 2018–2020. Helicobacter. 2024. doi:10.1111/hel.13028

BibTeX
@article{Okimoto2024,
  author = {Okimoto, Tadayoshi and Ando, Takashi and Sasaki, Makoto and Ono, Shoko and Kobayashi, Intetsu and Shibayama, Keigo and Chinda, Daisuke and Tokunaga, Kengo and Nakajima, Shigemi and Osaki, Takako and Sugiyama, Toshiro and Kato, Mototsugu and Murakami, Kazunari},
  title = {Antimicrobial‐resistant Helicobacter pylori in Japan: Report of nationwide surveillance for 2018–2020},
  journal = {Helicobacter},
  year = {2024},
  doi = {10.1111/hel.13028}
}
Kostenlos starten →